Amphastar Pharmaceuticals (AMPH) Gross Profit (2016 - 2025)
Historic Gross Profit for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $98.6 million.
- Amphastar Pharmaceuticals' Gross Profit fell 323.23% to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $357.0 million, marking a year-over-year decrease of 686.38%. This contributed to the annual value of $373.9 million for FY2024, which is 647.47% up from last year.
- Amphastar Pharmaceuticals' Gross Profit amounted to $98.6 million in Q3 2025, which was down 323.23% from $86.5 million recorded in Q2 2025.
- In the past 5 years, Amphastar Pharmaceuticals' Gross Profit ranged from a high of $108.4 million in Q3 2023 and a low of $44.9 million during Q1 2021
- Its 5-year average for Gross Profit is $76.0 million, with a median of $73.8 million in 2023.
- In the last 5 years, Amphastar Pharmaceuticals' Gross Profit skyrocketed by 8527.26% in 2023 and then tumbled by 987.31% in 2024.
- Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Gross Profit stood at $56.2 million in 2021, then increased by 26.56% to $71.2 million in 2022, then skyrocketed by 35.09% to $96.1 million in 2023, then decreased by 9.87% to $86.6 million in 2024, then grew by 13.85% to $98.6 million in 2025.
- Its Gross Profit stands at $98.6 million for Q3 2025, versus $86.5 million for Q2 2025 and $85.3 million for Q1 2025.